TIM-3 blockade restores NK cell exhaustion and leads to an increased NK cell cytotoxicity in several cancers [74,75], whereas the TIM-3 antibody agonist leads to a decrease in the cytotoxicity of NK cells [72]. The gene discussed is HAVCR2; the disease is cancer.